These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 18855859)

  • 1. The rationale for antibiotics in IBS.
    Di Stefano M; Corazza GR
    Am J Gastroenterol; 2008 Oct; 103(10):2652. PubMed ID: 18855859
    [No Abstract]   [Full Text] [Related]  

  • 2. Inflammation and microflora.
    Pimentel M; Chang C
    Gastroenterol Clin North Am; 2011 Mar; 40(1):69-85. PubMed ID: 21333901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations in the intestinal microbiota and functional bowel symptoms.
    Ringel Y; Carroll IM
    Gastrointest Endosc Clin N Am; 2009 Jan; 19(1):141-50, vii. PubMed ID: 19232285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of probiotics in IBS.
    Quigley EM
    J Clin Gastroenterol; 2008 Jul; 42 Suppl 2():S85-90. PubMed ID: 18542036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IBD and IBS: novel mechanisms and future practice. Preface.
    Travis SP; Spiller RC; Holzer P; Colombel JF
    Dig Dis; 2009; 27 Suppl 1():1-2. PubMed ID: 20203490
    [No Abstract]   [Full Text] [Related]  

  • 6. The small intestinal bacterial overgrowth. Irritable bowel syndrome hypothesis: implications for treatment.
    Vanner S
    Gut; 2008 Sep; 57(9):1315-21. PubMed ID: 18250127
    [No Abstract]   [Full Text] [Related]  

  • 7. Protease activated receptor 2: a new target for IBS treatment.
    Bueno L
    Eur Rev Med Pharmacol Sci; 2008 Aug; 12 Suppl 1():95-102. PubMed ID: 18924448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Using of adaptive biocontrolling feedbak in the treatment of irritable bowel syndrome].
    Trembach GA; Korot'ko GF
    Eksp Klin Gastroenterol; 2009; (1):67-71. PubMed ID: 19548425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duloxetine in the treatment of irritable bowel syndrome: an open-label pilot study.
    Brennan BP; Fogarty KV; Roberts JL; Reynolds KA; Pope HG; Hudson JI
    Hum Psychopharmacol; 2009 Jul; 24(5):423-8. PubMed ID: 19548294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lower gastrointestinal disorders in patients with irritable bowel syndrome.
    Jurcić D; Bilić A; Schwarz D; Luetic K; Marusić M; Vcev A; Gabrić M; Spoljarić L
    Coll Antropol; 2008 Sep; 32(3):755-9. PubMed ID: 18982748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postinfectious irritable bowel syndrome.
    Spiller R; Garsed K
    Gastroenterology; 2009 May; 136(6):1979-88. PubMed ID: 19457422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment experience of patients with irritable bowel syndrome complicated by constipations with medicinal preparation softovak].
    Ruchkina IN; Lychkova AE; Parfenov AI
    Eksp Klin Gastroenterol; 2007; (5):103-6. PubMed ID: 18389606
    [No Abstract]   [Full Text] [Related]  

  • 13. Postinfectious irritable bowel syndrome.
    Barbara G; Cremon C; Pallotti F; De Giorgio R; Stanghellini V; Corinaldesi R
    J Pediatr Gastroenterol Nutr; 2009 Apr; 48 Suppl 2():S95-7. PubMed ID: 19300138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathophysiological concepts of functional dyspepsia and irritable bowel syndrome future pharmacotherapy.
    Dobrek Ł; Thor PJ
    Acta Pol Pharm; 2009; 66(5):447-60. PubMed ID: 19894640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lactulose breath testing and irritable bowel syndrome.
    Grover M; Whitehead WE
    Am J Gastroenterol; 2008 Oct; 103(10):2652-3; author reply 2653-4. PubMed ID: 18855858
    [No Abstract]   [Full Text] [Related]  

  • 16. The benefits of loperamide in the treatment of patients with IBS or IBD. Introduction.
    Hanauer SB
    Rev Gastroenterol Disord; 2007; 7 Suppl 3():S1-2. PubMed ID: 18192960
    [No Abstract]   [Full Text] [Related]  

  • 17. [The use of bismuth tripotassium dicitrate (De-Nol), a promising line of pathogenetic therapy for irritated bowel syndrome with diarrhea].
    Iakovenko EP; Agafonova NA; Pokhal'skaia OIu; Kolganova AV; Nazarbekova RS; Ivanov AN; Davletshina IV; Popova EV; Prianishnikova AS; Ovchinnikova NI; Iakovenko AV; Aldiiarova MA; D'iachkoava AV; Gioeva IZ
    Klin Med (Mosk); 2008; 86(10):47-52. PubMed ID: 19069460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of quetiapine-XR on irritable bowel syndrome.
    Pae CU
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):1162-3. PubMed ID: 20609428
    [No Abstract]   [Full Text] [Related]  

  • 19. The power of placebo in pediatric functional gastrointestinal disease.
    Benninga MA; Mayer EA
    Gastroenterology; 2009 Oct; 137(4):1207-10. PubMed ID: 19717127
    [No Abstract]   [Full Text] [Related]  

  • 20. [Irritable bowel syndrome and inflammatory bowel disease: Is there a connection?].
    Mearin F; Perelló A; Balboa A
    Gastroenterol Hepatol; 2009 May; 32(5):364-72. PubMed ID: 19442413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.